The FDA has issued a warning letter related to BD Pyxis automated medication dispensing systems — technology that was part of ...

The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two ...

There has been no shortage of news covered across the diabetes and drug delivery markets over the course of 2024.

Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP ...

Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its glucose ...

Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership ...

MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

Qnovia’s nicotine replacement therapy device. [Image courtesy of Qnovia] Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform. Blue ...

Left, the Dexcom G7 CGM. Right, the Abbott FreeStyle Libre 2. [Images from Dexcom and Abbott] The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim ...